IKTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Inhibikase Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 11, 2026
$1.65−0.00 (-0.30%)
Close on Oct 19, 2026
- Market cap
- $287.17M
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Inhibikase Therapeutics has not reported a dividend
No dividend per share appears in Inhibikase Therapeutics's annual filings since fiscal 2019.